By analyzing single-cell responses to ketamine administration, a multinational team of researchers has identified a potassium channel that contributes to the long duration of ketamine administration.

Pharnext SAS has completed recruitment of an FDA-requested second phase III trial of its lead product, PXT-3003, in Charcot-Marie-Tooth disease type 1A (CMT1A), but now needs to raise €50 million (US$53.9 million) to stay solvent until the data read out in Q4 2023.

In two separate studies, researchers have identified how peripheral nerve injury can lead to increased pain sensitivity. The studies were published on May 25, 2022, in Nature and May 26, 2022, in Science, respectively. The mechanisms they identify could lead to new therapeutic approaches to chronic pain and/or pain hypersensitivity.